NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

AbbVie, Lilly, Roche and Takeda have demonstrated strong interest in licensing innovator oligonucleotides for CNS indications ...

Draig Therapeutics has secured £107m ($140m) in an oversubscribed Series A financing round to treat major neuropsychiatric ...

While the outlook for vaccines in the US looks bleak under Trump's administration, the UK is pressing ahead with securing its ...

Actio Biosciences has closed a Series B financing round, raising $66m for advancing the genetics-driven small molecule ...

The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...

BioOrbit CEO Dr Katie King said that pre-clinical studies of the crystals produced in space could start as early as 2026.

Orion Corporation has broadened its partnership with Glykos, focusing on the development of antibody-drug conjugates (ADCs).

The test is currently available in private healthcare facilities but there are hopes it may be adopted by the NHS.

FDA Commissioner Dr Marty Makary tried to allay industry concerns about recent cuts and outlined his agenda for the future.

The FDA launched a new Priority Review program, as uncertainty persists for the existing programme for paediatric disorders.